Jan 5, 2022 8:30 am EST Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
Nov 22, 2021 9:25 am EST LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
Oct 20, 2021 9:25 am EDT Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
Oct 13, 2021 9:25 am EDT Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
Aug 17, 2021 9:25 am EDT Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
Aug 3, 2021 9:25 am EDT LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
Jul 22, 2021 9:25 am EDT LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
Jul 13, 2021 9:25 am EDT Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
Jul 7, 2021 9:35 am EDT Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
Jun 2, 2021 9:35 am EDT Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
